TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05681689

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PyloPlus UBT System
Description: Breath will be analyzers for change in carbon 13 content in breath after ingestion of enriched carbon 13 urea.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Histology
Description: Biopsy specimen fixed with 10% buffered formalin cut into 4mm sections, stained with Giemsa stain, and examined by experienced pathologist.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rapid Urease Test
Description: Biopsy specimen obtained and placed onto Rapid Urease Test

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Comparator Breath Test
Description: Breath will be analyzers for change in carbon 13 content in breath after ingestion of enriched carbon 13 urea.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Stool Antigen Test
Description: An antigen test performed via a laboratory to test patient's stool for H. pylori
Study: NCT03567824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium L-lactate dihydrate
Description: Magnesium L-lactate dihydrate 10 mEq extended release caplets

Intervention type: DRUG
Group type: OTHER
Intervention: Magnesium L-lactate dihydrate
Description: Magnesium L-lactate dihydrate 10 mEq extended release caplets

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo Oral Tablet
Description: Placebo will have the same appearance, taste, odor and mode of administration as MLD10.
Study: NCT05369195

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LAAC procedure with the use of transcatheter cerebral protection system
Description: After aortography the cerebral protection system will be delivered to cerebral arteries through radial access before accessing the left atrium.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: LAAC procedure without the use of transcatheter cerebral protection system
Description: Only the aortography through radial access will be done before accessing the left atrium.
Study: NCT06193135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corifolitropin Alfa
Description: Patients will receive a single dose of Colifolitropin alfa, then will receive daily dose of Folitropin Beta since triggering criteria are met.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folitropin Beta
Description: Patient will receive daily dose of Folitropin Beta since triggering criteria are met.
Study: NCT05512975

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dairy protein porridge arm
Description: Regular porridge ingredients with additional delical whey protein fortification

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant protein porridge arm
Description: Regular porridge ingredients with the addition of extruded soya protein fortification and soya milk instead of regular dairy milk

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control Porridge arm
Description: Regular porridge ingredients with no additional protein fortification
Study: NCT05230836

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-frequency alternating current stimulation
Description: For electrical stimulation in the active groups, unmodulated alternating currents with a symmetrical rectangular waveform of 30 kHz, 40 kHz and 50 kHz will be applied. The current intensity shall be adjusted individually for each participant by increasing the current intensity until the participant reports a strong but comfortable tingling sensation just below the excitomotor threshold on the palmar aspect of the hand in the dermatomes innervated by the median nerve. The intensity of the current shall be adjusted every two minutes if the tingling sensation decreases. This protocol has been used in previous studies conducted by our research group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-frequency alternating current stimulation
Description: For electrical stimulation in the active groups, unmodulated alternating currents with a symmetrical rectangular waveform of 30 kHz, 40 kHz and 50 kHz will be applied. The current intensity shall be adjusted individually for each participant by increasing the current intensity until the participant reports a strong but comfortable tingling sensation just below the excitomotor threshold on the palmar aspect of the hand in the dermatomes innervated by the median nerve. The intensity of the current shall be adjusted every two minutes if the tingling sensation decreases. This protocol has been used in previous studies conducted by our research group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-frequency alternating current stimulation
Description: For electrical stimulation in the active groups, unmodulated alternating currents with a symmetrical rectangular waveform of 30 kHz, 40 kHz and 50 kHz will be applied. The current intensity shall be adjusted individually for each participant by increasing the current intensity until the participant reports a strong but comfortable tingling sensation just below the excitomotor threshold on the palmar aspect of the hand in the dermatomes innervated by the median nerve. The intensity of the current shall be adjusted every two minutes if the tingling sensation decreases. This protocol has been used in previous studies conducted by our research group

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham current stimulation
Description: Sham electrical stimulation will be performed with the same equipment and electrodes as in the active groups without the participants and the evaluator having a view of the device screen. The intensity of the current will be increased for 30 seconds until the sensory threshold (strong but comfortable tingling sensation) is exceeded and once the threshold is reached, the intensity will be reduced to 0 mA with 30 seconds ramp down. Participants will not receive electrical current during the rest of the placebo intervention. This protocol was used in other studies with similar interventions to blind participants.
Study: NCT06000124

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regulation Exercises Program
Description: The regulated exercise program includes the use of elastic bands, Qigong, and dance et al.
Study: NCT04474509

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FACT Module Engagement
Description: Focused- Acceptance and Commitment Therapy. Third-wave Cognitive Behavioral Therapy (Psychological intervention)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FACT Module Openness
Description: Focused- Acceptance and Commitment Therapy. Third-wave Cognitive Behavioral Therapy (Psychological intervention)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FACT Module Awareness
Description: Focused- Acceptance and Commitment Therapy. Third-wave Cognitive Behavioral Therapy (Psychological intervention)
Study: NCT05253989

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VR Intervention
Description: VR Device that allows a patient to play games based on the EMG activity in the upper limb.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VR Intervention
Description: VR Device that allows a patient to play games based on the EMG activity in the upper limb.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FES
Description: Functional Electrical Stimulation used to increase motor excitability whilst engaging in VR rehabilitation
Study: NCT04677179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3471851
Description: administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3471851
Description: administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LY3471851
Description: administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered SC
Study: NCT04472000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Study participants in the verum group receive one capsule of Burgerstein Vitamin C retard 500mg b.i.d. with treatment starting in the evening on the day of the operation for a total of 50 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group receives one placebo capsule b.i.d. with treatment starting in the evening on the day of the operation for a total of 50 days.
Study: NCT05321654

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education for Behavior Modification
Description: Please see arm description for a detailed description of the intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Corrective Exercise Program
Description: Please see arm description for a detailed description of the intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Corrective Exercise Program
Description: Please see arm description for a detailed description of the intervention
Study: NCT05398991

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the Coronary Covered Stents System manufactured by Shanghai MicroPort Medical (Group) Co., Ltd.
Description: the Coronary Covered Stents System contains a covered stent and a delivery system
Study: NCT05225194

Intervention type: OTHER
Intervention: COVID-19
Description: SARS-CoV-2 infection

Intervention type: OTHER
Intervention: ARDS
Description: Acute respiratory distress syndrome

Intervention type: OTHER
Intervention: ARDS
Description: Acute respiratory distress syndrome
Study: NCT05338801

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menthol-flavored e-cigarette
Description: All participants will complete a lab visit where they will use menthol-flavored e-cigarette ad libitum for up to 60 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco-flavored e-cigarette
Description: All participants will complete a lab visit where they will use tobacco-flavored e-cigarette ad libitum for up to 60 minutes.
Study: NCT06060015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5mg bupivacaine
Description: Anesthetic technique, the patient receives subarachnoid hyperbaric bupivacaine at a dose of 5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10mg bupivacaine
Description: Anesthetic technique, the patient receives subarachnoid hyperbaric bupivacaine at a dose of 10 mg
Study: NCT05439590

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High dose CSO
Description: Participants in the high-dose CSO arm of the study will consume two smoothies containing a total of 60 g of CSO per day for 4 weeks.
Study: NCT05583812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB2001 for inhalation
Description: FB2001 once or twice daily inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB2001 for inhalation
Description: FB2001 once or twice daily inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB2001 for inhalation
Description: FB2001 once or twice daily inhalation
Study: NCT05439590

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low dose CSO
Description: Participants in the low-dose CSO arm of the study will consume two smoothies containing a total of 30 g of CSO per day for 4 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low dose OO
Description: Participants in the low-dose OO arm of the study will consume two smoothies containing a total of 30 g of OO per day for 4 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High dose OO
Description: Participants in the high-dose OO arm of the study will consume two smoothies containing a total of 60 g of OO per day for 4 weeks.
Study: NCT05344781

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire regarding relationship and sexual satisfaction

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire regarding relationship and sexual satisfaction
Study: NCT06472830

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT03822793

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patient will receive an intravenous perfusion of NaCl (sodium chloride 9%; placebo) intravenous over 9 minutes, starting at the time of surgical incision.
Study: NCT05583812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB2001 for inhalation
Description: FB2001 once or twice daily inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB2001 for inhalation placebo
Description: FB2001 placebo once or twice daily inhalation
Study: NCT03822793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 1: perfusion of 300 mg Exacyl
Description: Patient will receive an intravenous perfusion of 300 mg Exacyl (tranexamic acid) intravenous (IV) over 9 minutes, starting at the time of surgical incision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 2: perfusion of 500 mg Exacyl
Description: Patient will receive an intravenous perfusion of 500 mg Exacyl (tranexamic acid) intravenous (IV) over 9 minutes, starting at the time of surgical incision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 3: perfusion of 1000 mg Exacyl
Description: Patient will receive an intravenous perfusion of 1000 mg Exacyl (tranexamic acid) intravenous (IV) over 9 minutes, starting at the time of surgical incision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 4: perfusion of 3000 mg Exacyl
Description: Patient will receive an intravenous perfusion of 3000 mg Exacyl (tranexamic acid) intravenous (IV) over 9 minutes, starting at the time of surgical incision.
Study: NCT05977036

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DiviTum® TKa assay
Description: Will be utilized for determination of serum enzymatic activity of TK1 according to the manufacturer's instructions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DiviTum® TKa assay
Description: Will be utilized for determination of serum enzymatic activity of TK1 according to the manufacturer's instructions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDK4/6 + Endocrine therapy
Description: FDA-approved endocrine therapy plus CDK4/6 inhibitor. Ribociclib is the preferred CDK4/6 inhibitor. In the event this drug cannot be obtained due to insurance authorization or if there are specific side effect profile concerns from the treating physician, an alternative CDK4/6 inhibitor is allowed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDK4/6 + Endocrine therapy
Description: FDA-approved endocrine therapy plus CDK4/6 inhibitor. Ribociclib is the preferred CDK4/6 inhibitor. In the event this drug cannot be obtained due to insurance authorization or if there are specific side effect profile concerns from the treating physician, an alternative CDK4/6 inhibitor is allowed.
Study: NCT05583812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB2001 for inhalation placebo
Description: FB2001 placebo once or twice daily inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB2001 for inhalation placebo
Description: FB2001 placebo once or twice daily inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB2001 for inhalation placebo
Description: FB2001 placebo once or twice daily inhalation
Study: NCT05094557

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Group 1: Body swapping VR intervention + psychoeducational video + Treatment As usual
Description: The patient will be embodied in his/her own avatar and will maintain a conversation with a counsellor's avatar of his/her choice. Once the experiment starts, the patient, embodied in his/her own body, will start describing his/her problem in terms of subjective experiences of being obese in daily life. Then, he/she will be body swapped to the counsellor's body and try to respond to the problem just manifested by the patient. The crucial aspect here is that the patient, from the counsellor's viewpoint, will see a representation of his/her real body when looking at the patient's avatar speaking and moving. Therefore, the patient will have the opportunity to see himself/herself in first person (1PP) and second person (2PP) perspectives.
Study: NCT05102175

Intervention type: OTHER
Intervention: Focus Group
Description: Eligible participants will be invited to a semi-structured focus group discussion. Each group will include 8 -12 participants.
Study: NCT05275400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Efsitora Alfa
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Degludec
Description: Administered SC
Study: NCT05094557

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Group 2: VR intervention without body swapping + psychoeducational video + Treatment As usual
Description: Participants from the Experimental Group 2 will be embodied in their own body and will participate in pre-established discourse provided by the chosen counsellor, who will ask about the perceived barriers for engagement with a healthier lifestyle and will give practical recommendations about how to achieve a healthier and happier life, in terms of healthy eating and physical activity. No body swapping will take place for this group. Participants will also continue receiving Treatment As usual plus a Psychoeducational video with useful information about how to engage with a healthier lifestyle.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group: Psychoeducational video + Treatment As usual
Description: Participants from the Control Group will receive their Treatment As Usual plus a Psychoeducational video. Treatment as usual will consist of regular medical, nutritional and/or psychiatric follow-ups with the obesity specialists of the Vall d´ Hebron University Hospital and standard routine tests. These visits aim to provide practical recommendations about how to achieve a gradual weight loss and engage more with physical exercise.
Study: NCT05987202

Intervention type: OTHER
Intervention: DA closure in a population of premature infants
Description: Evaluate the incidence of DA closure in a population of premature infants treated with BTM per os for bronchopulmonary dysplasia
Study: NCT04720248

Intervention type: DRUG
Intervention: Metamizole
Description: Patients will receive metamizole intraoperatively and throughout 48h postoperatively.
Study: NCT04876872

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT05693701

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation Strategy Bundle
Description: Bundle includes multimodal communications to notify donors about high cholesterol and its treatment, website with resources, and an optional care navigator. Resources for their primary care provider will also be disseminated.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care notification
Description: Carter BloodCare will notify participants of their high cholesterol, potential for genetic causes, and recommendation to see their care provider by sending its routine, standard notification letter. These participants will also be eligible to receive the intervention bundle at the end of the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care notification
Description: Carter BloodCare will notify participants of their high cholesterol, potential for genetic causes, and recommendation to see their care provider by sending its routine, standard notification letter. These participants will also be eligible to receive the intervention bundle at the end of the study.
Study: NCT04796012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Feasibility and RMS Cohorts: Administered at 15 mg/kg (max 1,200 mg) IV on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Feasibility and RMS Cohorts: Administered at 15 mg/kg (max 1,200 mg) IV on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Feasibility and RMS Cohorts: Administered at 1.5 mg/m\^2 (max 2 mg) IV on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Feasibility and RMS Cohorts: Administered at 1.5 mg/m\^2 (max 2 mg) IV on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Feasibility and RMS Cohorts: Administered at 50 mg/m2 IV on Days 1-5 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Feasibility and RMS Cohorts: Administered at 50 mg/m2 IV on Days 1-5 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Feasibility and RMS Cohorts: Administered at 100 mg/m\^2 (max 200 mg) IV or PO 1 hour before irinotecan injection on Days 1-5 if each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Feasibility and RMS Cohorts: Administered at 100 mg/m\^2 (max 200 mg) IV or PO 1 hour before irinotecan injection on Days 1-5 if each 21-day cycle
Study: NCT05860634

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter self-discontinuation
Description: Self-discontinuation of a transurethral catheter
Study: NCT06598449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenfluramine
Description: Clear, cherry flavored oral solution
Study: NCT06665256

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rapcabtagene autoleucel
Description: Single infusion of rapcabtagene autoleucel

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator Option
Description: Investigator choice of treatment as per protocol
Study: NCT06611254

Intervention type: DEVICE
Intervention: Contrast enhanced ultrasound imaging (CEUS) and post processing with ULM
Description: CEUS is a contrast based ultrasound technique and ULM (Ultrasound Localization Microscopy) is a post-processing bioinformatical method to quantify microvascular architecture and perfusion dynamics.